Clinical trials: Skin Texture Disorder
Metastatic Melanoma
Response to Pembrolizumab in Metastatic Melanoma: Computed Tomography Texture Analysis as a Predictive Biomarker
Studies have shown that the study drug, pembrolizumab, works by helping the immune system. In this way, pembrolizumab may help to slow the growth of melanoma or may cause cancer cells to die.
- Trial name
- NCT02740920
- Testing
- Pembrolizumab, CT Scan
- Where
- 5 sites in Canada
- Volunteers
- 9 people
- Sponsor
- Canadian Cancer Trials Group
Pigment Skin
Combining Broad Based Light (BBL), Fractionated 1927 (MOXI) and Dual Wavelength 2940/1470 (HALO)
This is a single-site, non-randomized, non-controlled study at UT Southwestern Medical Center at Dallas in the Department of Plastic Surgery.
- Trial name
- NCT06091215
- Testing
- Sciton Joule System
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center